ZyVersa: This Drug Maker Is Targeting Critical Diseases With Novel Approaches

Steve Glover, Co-Founder, Chairman, CEO, & President of ZyVersa Therapeutics, Inc. ZVSA, was recently a guest on Benzinga’s All-Access.

ZyVersa is a clinical-stage specialty biopharmaceutical company leveraging advanced proprietary technologies to develop first-in-class drugs for patients with inflammatory or kidney diseases with high unmet medical needs.

The company currently has two novel drugs in the development pipeline. IC 100, an “ASC inflammasome inhibitor” treats inflammatory diseases. VAR200 is a “Cholesterol Efflux Mediator” targeting kidney disease. 

Watch the full interview here:

Featured photo by danilo.alvesd on Unsplash

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.